
Rechallenging Immunotherapy Plus Anlotinib in Lung Cancer
In the relentless battle against advanced non-small cell lung cancer (NSCLC), a groundbreaking retrospective study has shed light on the promising potential of combining immune checkpoint inhibitors (ICIs) with anlotinib as a rechallenge therapy after …